Trial Profile
Efficacy of low-dose erlotinib as maintenance therapy in patients of lung adenocarcinoma with EGFR mutation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 09 Jul 2013 Planned end date changed from 1 Apr 2015 to 1 Apr 2020 as reported by University Hospital Medical Information Network - Japan record.
- 09 Jul 2013 Additional lead trial centres added as reported by University Hospital Medical Information Network - Japan record.
- 25 Apr 2011 New trial record